We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Iq-ai Limited | LSE:IQAI | London | Ordinary Share | JE00BD4H0R42 | ORD GBP0.01 |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.05 | 3.23% | 1.60 | 21,122 | 16:29:39 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 1.50 | 1.70 | 1.60 | 1.55 | 1.55 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Florists | 536k | -512k | -0.0028 | -5.71 | 2.92M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:29:39 | O | 197 | 1.70 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 05/3/2024 | 07:00 | UK RNS | IQ-AI Limited Grant of Options |
| 01/3/2024 | 08:22 | UK RNS | IQ-AI Limited Holding(s) in Company |
| 01/3/2024 | 08:20 | UK RNS | IQ-AI Limited Holding(s) in Company |
| 26/2/2024 | 07:00 | UK RNS | IQ-AI Limited Result of Broker Option and Total Voting Rights |
| 22/2/2024 | 14:02 | ALNC |  IN BRIEF: IQ-AI shares sink on discounted placing fundraise |
| 22/2/2024 | 07:00 | UK RNS | IQ-AI Limited Placing and Broker Option |
| 09/2/2024 | 13:38 | ALNC | IQ-AI subsidiary asked by FDA to resubmit and modify application |
| 09/2/2024 | 12:49 | UK RNS | IQ-AI Limited FDA Application Update |
| 02/2/2024 | 08:56 | ALNC | IN BRIEF: IQ-AI celebrates USD100,000 grant for subsidiary |
| 02/2/2024 | 08:39 | UK RNS | IQ-AI Limited IB awarded a $100,000 grant |
Iq-ai (IQAI) Share Charts1 Year Iq-ai Chart |
|
1 Month Iq-ai Chart |
Intraday Iq-ai Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 10/4/2024 | 16:56 | AI Creating the Standard in Image Quantification - (Medical/Neuro)) | 1,619 |
| 22/2/2024 | 11:52 | Imaging Quantification - Artificial Intelligence | 7,454 |
| 20/2/2024 | 16:35 | Colwyn Bay Free | 24 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 15:29:39 | 1.70 | 197 | 3.35 | O |
| 15:29:36 | 1.60 | 11,812 | 188.99 | O |
| 14:04:39 | 1.60 | 93 | 1.49 | O |
| 11:48:42 | 1.52 | 5,000 | 75.81 | O |
| 09:02:11 | 1.50 | 66 | 0.99 | O |
| Top Posts |
|---|
Posted at 26/4/2024 09:20 by Iq-ai Daily Update Iq-ai Limited is listed in the Florists sector of the London Stock Exchange with ticker IQAI. The last closing price for Iq-ai was 1.55p.Iq-ai currently has 182,621,390 shares in issue. The market capitalisation of Iq-ai is £2,921,942. Iq-ai has a price to earnings ratio (PE ratio) of -5.71. This morning IQAI shares opened at 1.55p |
Posted at 05/3/2024 11:43 by festario Looks like people are bailing out at a big loss now. Why wouldn't they?Trevor has proved yet again to be entirely untrustworthy to any self respecting investor. The options price is pathetic and gives no incentive whatsoever to develop the business.One rampy RNS, like he's famous for, and both he, Brett Skelly and Mike Schmainda can grab a load of free cash, by converting and flipping the shares instantly. That's after dragging the share price down here deliberately so they could load up. Another massive red flag has been hoisted today. |
Posted at 05/3/2024 07:23 by hulk2004 You could also argue getting options done before good news, can only make money on options if share price increases from 1.9p, currently 1.8p on the bid, MS got most of the options and he is at the coal face so he knows what’s coming, not to say I am overly happy about option price though. |
Posted at 24/2/2024 19:49 by hollywood6 Yes, I remember the comments well. Including stonechecker....We have also seen some big spikes in the share price over the years. Pis could ha e sold multiple times and made some cash. |
Posted at 24/2/2024 19:39 by hollywood6 But will we see a big increase in share price following this? That's the key. AND how big an increase? I'm happy to forgive if we hit 10p |
Posted at 31/1/2024 15:51 by cliffv69 Whether it's FAB or TB, it all ends up in the same pocket eventually. If TB buys now the price has dropped, wouldn't that be classed as purposely selling to manipulate the share price? After all, those CLN's didn't need to be converted straight after the spike did they? The company only gained a small sum for this. Tactically TB is either a genius or a car crash. All I can say is - wait for his retirement selling. |
Posted at 31/1/2024 15:08 by howdlep Cliff,FAB aren't buying back. They sold on the open market in order to allow TB to exercise the loan note conversion, which took the the concert holding back up to near 30%. They have since sold further shares, leaving TB headroom for future corporate transactions. Obviously, the FAB selling hit the share price causing it fall back as you highlighted. |
Posted at 31/1/2024 14:36 by cliffv69 Philip, So if it's business as usual and all above board like you say. Why has the share price almost halved since it's 5p plus spike over the last month? Could it be manipulated by those FAB sales to reduce the share price for them to buy back in cheaper whilst taking a profit? Could it be that shareholders see what I see and that if anything big was going to happen soon, why would TB want to upset the apple cart now? I know you are IQAI's biggest fan and probably hold many shares but think logically for a minute. |
Posted at 31/1/2024 12:23 by cliffv69 Well if that's the case they had already exceeded the 30 percent since 20th November 2023 as the overall combined percentage was 31 percent. What ever way you want to make it up it's not an unknown that TB and family will always sell once they see a profit to be made so the fact he likes to use trading more as a personal play, it effects the share price therefore the shareholders. I suggest you buy more and help IQAI get to the next spike. |
Posted at 12/1/2024 09:14 by howdlep For those not reading the LSE bb, here is my post:-As I have said previously, TB and FAB are acting in concert and so their combined holding must remain under 30%. Otherwise an offer would need to be made for the remaining shares in the company. With regard to the loan notes, they can be repaid in shares or in money, on or before the expiry date. In both cases, with the associated 6% coupon (interest). Now one of those loan notes expires in March 24, the other the following year. So the Board have to act now to ensure the March 24 conversion completes asap, otherwise they would have to place to pay back the money. Obviously, the latter is not going to happen. So whilst this is incredibly frustrating, once it completes then normal services can be resumed. In fact, with a rapidly increasing share price. In the meantime, don't rule out some good news dropping that would cause a big gap up. That would be so annoying for those looking to sell and buy back cheaper. But that is all part of the investment game. Trade in a manner that best suits your circumstances. Good luck one and all. |
Posted at 20/8/2023 20:11 by spurs90 #IQAI #stockpick#IQAI On Friday afternoon announced a deal for IB Neuro and IB Delta T1 to be embedded in GE HealthCare's (GEHC) MR Smart Subscription. IB Neuro and IB Delta T1 maps are applications that accept magnetic resonance imaging (MRI) data as input and automatically compute quantitative and proprietary images as output. The global MRI market is projected to grow at a rate of 7% and surpass $11 billion by 2030, and GEHC is a leading player in that market. A factor driving that growth are complementary advancements in imaging software, such as IB's quantitative solutions. Their software is available via the newly launched Bayer Calantic platform. They also have a drug in phase 1 but have already stated it will be entering phase 2 and this will be funded by a partnership with a major pharmaceutical company. They have recently received orphan drug status for this drug for both adult patients and children for the treatment of glioblastoma(brain cancer). They have recently announced they will be starting a second phase 1 study for children and have initiated discussions with several sites who have expressed a collaborative interest. Paediatric brain tumour research and development receive significant philanthropic funding. Consortiums of non-profits exist that help fund clinical trials for children, either partially or in their entirety. #IQAI have already made connections and introduced their progress to one organization. In turn, they identified several hospitals with whom they have established relationships so we should receive an update imminently for this. The ultimate objective of our program is to obtain regulatory approval for a medicine that could offer a positive impact on the length and quality of life for patients who otherwise have no other options. As the trial process continues, their efforts to identify and secure an accelerated regulatory approval pathway will also continue. Pathways, such as Fast Track Designation and Paediatric Rare Disease Priority Review Voucher (PRD-PRV), exist to expedite the development, review, and approval of promising drugs that treat diseases such as GBM and paediatric cancers. Paediatric rare disease priority review vouchers have recently sold for over $100m with examples from Sarepta Therapeutics and bluebird bio both selling theirs to major pharmaceutical companies. #IQAI Also have patented artificial intelligence ("AI") technology, IB Zero G generates enhanced "with contrast" images using only non-contrast (0% gadolinium) images as input. The FDA's response to the FDA 510(k) submission concluded that IB Zero G™ was too novel and unique a product and subsequently directed IB to pursue a different regulatory clearance pathway. IB is compiling additional documentation in preparation for a pre-submission meeting with the FDA and plans to submit a "de novo" application in the second half of the year. The de novo request is a market clearance pathway designed for novel medical devices for which no legally marketed predicate device exists to demonstrate substantial equivalence. So we could receive an update on this imminently also. #IQAI shares have previously traded as high as 24p and as low as 1p with all this recent positive news announced they could in my opinion be headed back to 20p+ although this time they have a dual listing on the us otc market so we could see new all time highs if it gets picked up over there with the us investors having deeper pockets. There are 183m shares in issue and the ceo holds 29% of these so it’s in his best interest for these to succeed. Currently shares are 3.8/4p giving a market capitalisation of £6.9m. With all these factors and with their footprint in the USA only getting bigger and deals being signed better this share will in my opinion be multiples of today’s price in the very near future. #IQAI #stockpick Numbers are end of June.. Cash 90k Income 282k Profit 278k Costs 578k (Admin 572k, Finance 5k etc) Loss 300k Cash used in operations is 224k. More than 45 different hospitals and healthcare systems are at varying stages of evaluating our software, with more sites entering the sales pipeline. This step-change in pre-sales activity is approximately a seven-fold increase over previous periods and is due, in large part, to the traction gained from our platform partners including TeraRecon (Eureka) and Bayer (Calantic). These partners have the medical expertise and marketing reach to sell our technologies into large existing installed customer bases and have ample sales and marketing resources to win clients. It is a relatively easy up-sell for IB's partners' sales teams to activate IB's technology on platforms already being used clinically. The number of sites evaluating our software continues to increase. Thus, we are optimistic about the revenue activity and anticipate a step-change starting in the 2nd half of 2023. Plus we now have the GE health care network to sell into. GE Health has installed 4 million scanners and other medical devices worldwide. GEHC total assets $28bil. They invest over $1bil annually in R&D. 259k patients supported daily using imaging technology. 2bil patients scanned annually. Lots to look forward to in regards to upcoming updates |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
